Scilex Holding (SCLX) Q2 2025 earnings summary

Executive summary

• Net revenue for Q2 2025 was $9.9M, down 40% year-over-year, mainly due to lower ZTlido sales volume; net loss widened to $44.0M from $37.6M in Q2 2024.

• Six-month net revenue was $14.9M, down 45% year-over-year; net loss for the period was $70.1M, with an accumulated deficit of $631.4M as of June 30, 2025.

• Management concluded there is substantial doubt about the ability to continue as a going concern for the next year due to negative working capital and ongoing losses.

Financial highlights

• Q2 2025 net revenue: $9.9M (Q2 2024: $16.4M); six-month net revenue: $14.9M (2024: $27.3M).

• Q2 2025 net loss: $44.0M (Q2 2024: $37.6M); six-month net loss: $70.1M (2024: $62.0M).

• Cash and cash equivalents at June 30, 2025: $4.1M.

• Operating cash flow for six months: $13.1M; net cash used in financing activities: $11.7M.

• Accumulated deficit: $631.4M as of June 30, 2025.

Outlook and guidance

• Management expects continued losses and negative cash flows, with substantial additional funding required to support operations and growth strategy.

• Plans to seek additional capital through equity, debt, collaborations, or strategic transactions; future liquidity depends on successful commercialization of ZTlido, GLOPERBA, and ELYXYB.